Anocca, a Swedish biotechnology firm, has successfully raised approximately $46 million to support the early-stage clinical trials of their non-viral gene-edited TCR-T cell therapy, VIDAR-1, targeting mutant KRAS in pancreatic cancer. This funding will not only fuel the clinical trials but also drive forward the company’s preclinical pipeline, showcasing a significant step towards combating this challenging disease.
The financing round was led by Mellby Gård, an investment entity, along with contributions from Ramsbury, AMF, and existing shareholders, demonstrating a strong vote of confidence in Anocca’s innovative approach. The participation of new investors further underscores the potential and promise of Anocca’s cell therapy platform in addressing unmet medical needs in pancreatic cancer treatment.
Anocca has initiated recruitment for Phase I of the cell therapy trial, a multi-center study spanning university hospitals in Denmark, Germany, the Netherlands, and Sweden. The VIDAR-1 trial, designed as an umbrella study, encompasses various products targeting oncogenic driver KRAS mutations in pancreatic ductal adenocarcinoma (PDAC), with plans to enroll up to 20 subjects per product across Phase I/II trials.
The current Phase I stage is active at eight locations across four countries, with expansion plans into additional sites and nations during Phase II. Eligibility for enrollment in the trial hinges on subjects possessing specific HLA and KRAS mutations that align with the available products, ensuring a targeted approach to treatment delivery. The strategic expansion of the trial locations underscores Anocca’s commitment to broadening patient access and diversifying clinical insights.
SEB Corporate Finance provided financial advisory services during the transaction, emphasizing the importance of strategic financial planning in advancing novel therapies. Legal counsel from Mannheimer Swartling and HWF Advokater further ensured the smooth execution of the funding round, highlighting the intricate regulatory landscape surrounding cell therapy development and commercialization.
Reagan Jarvis, CEO and co-founder of Anocca, expressed gratitude towards investors for their unwavering support in advancing the company’s TCR-T cell therapy products into clinical settings. Jarvis highlighted Anocca’s unique discovery platform and in-house manufacturing capabilities as key strengths driving the translation of scientific innovation into tangible patient benefits, underscoring the transformative potential of cell therapies in addressing critical unmet needs.
In March 2025, Anocca received regulatory authorization from authorities in four European nations to proceed with the Phase I/II VIDAR-1 trial, marking a pivotal milestone in the company’s clinical development journey. The approval signals regulatory confidence in Anocca’s rigorous research and development processes, paving the way for further advancements in the field of cell-based therapies for pancreatic cancer.
Takeaways:
– Anocca’s successful funding round of $46 million signifies growing investor confidence in the potential of cell therapies for pancreatic cancer treatment.
– The VIDAR-1 trial’s innovative approach targeting mutant KRAS mutations in pancreatic cancer showcases Anocca’s commitment to addressing specific oncogenic drivers.
– Strategic partnerships with financial advisors and legal counsels highlight the importance of navigating complex regulatory landscapes in advancing novel therapies.
– Regulatory authorization for Anocca’s Phase I/II trial underlines the company’s adherence to rigorous scientific and ethical standards in bringing innovative treatments to patients.
Tags: regulatory, cell therapy, clinical trials
Read more on finance.yahoo.com